Summary of COVID-19 atilotrelvir studies
Studies
Meta Analysis
Hide extended summaries
1,217 patient GST-HG171 early treatment RCT: 13% faster recovery (p=0.03) and 25% faster viral clearance (p<0.0001).
RCT 1,213 outpatients with mild-to-moderate COVID-19 in China showing a shorter time to sustained recovery and faster viral clearance with GST-HG171 (atilotrelvir) plus ritonavir.
May 2024, eClinicalMedicine, https://www.sciencedirect.com/science/article/pii/S2589537024001615, https://c19p.org/lu5
1,217 patient GST-HG171 early treatment RCT: 13% faster recovery (p=0.03) and 25% faster viral clearance (p<0.0001).
RCT 1,213 outpatients with mild-to-moderate COVID-19 in China showing a shorter time to sustained recovery and faster viral clearance with GST-HG171 (atilotrelvir) plus ritonavir.
May 2024, eClinicalMedicine, https://www.sciencedirect.com/science/article/pii/S2589537024001615, https://c19p.org/lu5
Please send us corrections, updates, or comments.
c19early involves the extraction of 100,000+ datapoints from
thousands of papers. Community updates
help ensure high accuracy.
Treatments and other interventions are complementary.
All practical, effective, and safe
means should be used based on risk/benefit analysis.
No treatment or intervention is 100% available and effective for all current
and future variants.
We do not provide medical advice. Before taking any medication,
consult a qualified physician who can provide personalized advice and details
of risks and benefits based on your medical history and situation. FLCCC and WCH
provide treatment protocols.
Thanks for your feedback! Please search before submitting papers and note
that studies are listed under the date they were first available, which may be
the date of an earlier preprint.